These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20362232)

  • 1. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.
    Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY
    Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
    Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
    Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.
    Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F
    Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K; Kodama A; Ohyashiki JH
    Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.
    Veselovska J; Pospisilova D; Pekova S; Horvathova M; Solna R; Cmejlova J; Cmejla R; Belickova M; Mihal V; Stary J; Divoky V
    Leuk Res; 2008 Mar; 32(3):369-77. PubMed ID: 17719087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
    Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
    Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
    Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.